The Oncology Institute, Inc.
TOI
$2.96
-$0.14-4.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 502.73M | 461.04M | 424.38M | 403.15M | 393.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 502.73M | 461.04M | 424.38M | 403.15M | 393.41M |
| Cost of Revenue | 426.29M | 392.73M | 360.62M | 343.88M | 339.42M |
| Gross Profit | 76.44M | 68.31M | 63.75M | 59.28M | 54.00M |
| SG&A Expenses | 105.57M | 102.39M | 103.79M | 104.75M | 107.83M |
| Depreciation & Amortization | 6.94M | 7.02M | 6.87M | 6.58M | 6.29M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 538.81M | 502.14M | 471.28M | 455.21M | 453.53M |
| Operating Income | -36.08M | -41.11M | -46.90M | -52.06M | -60.12M |
| Income Before Tax | -60.74M | -66.41M | -66.02M | -64.36M | -64.66M |
| Income Tax Expenses | -131.00K | -131.00K | -131.00K | -- | -- |
| Earnings from Continuing Operations | -60.61 | -66.28 | -65.89 | -64.36 | -64.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.61M | -66.28M | -65.89M | -64.36M | -64.66M |
| EBIT | -36.08M | -41.11M | -46.90M | -52.06M | -60.12M |
| EBITDA | -29.14M | -34.09M | -40.04M | -45.48M | -53.83M |
| EPS Basic | -0.56 | -0.64 | -0.68 | -0.70 | -0.71 |
| Normalized Basic EPS | -0.40 | -0.46 | -0.49 | -0.50 | -0.54 |
| EPS Diluted | -0.57 | -0.65 | -0.69 | -0.71 | -0.72 |
| Normalized Diluted EPS | -0.40 | -0.46 | -0.49 | -0.50 | -0.54 |
| Average Basic Shares Outstanding | 369.23M | 343.43M | 321.48M | 303.03M | 300.16M |
| Average Diluted Shares Outstanding | 369.23M | 343.43M | 321.48M | 303.03M | 300.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |